UNSPSC 51312407: Methapyrilene hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C14H19N3S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 00S42N58OM, chemically known as 1,2-ethanediamine, n,n-dimethyl-n-2-pyridinyl-n-(2-thienylmethyl)-, monohydrochloride but more generally known as methapyrilene hydrochloride, which bears US NIH Compound Identifier 8667. European Medicines Agency schedules Methapyrilene hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03211MIG.

UNSPSC 51312407 Methapyrilene hydrochloride is a Commodity code that, based on recent state and local procurement activity, does not map cleanly to the work actually being solicited under it. Recent opportunities posted under or near this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products—none of which center on methapyrilene hydrochloride, a specific pharmaceutical compound. The mismatch suggests either inconsistent coding by issuing agencies or that the code is tagged to broader pharmaceutical-sourcing initiatives that encompass multiple active compounds and product categories. State and local buyers using this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (MMCAP, administered by Minnesota Department of Administration's Office of State Procurement), indicating participation across health authorities, counties, and cooperative vehicle administrators.

Geographic activity centers on Texas, Minnesota, and Florida based on recent postings. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB60459723LAS, due July 26, 2023); Texas HHS Commission's RFI soliciting vendor capabilities for direct-to-manufacturer prescription programs (HHS0017013, posted April 3, 2026); and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across multiple states including Oregon (S1070000015802, due March 26, 2026). The code shows active procurement volume but reflects a broad, mixed portfolio of pharmaceutical and health-product sourcing rather than a narrowly focused category. Vendors pursuing opportunities under this code should verify the specific active compounds and product lines requested in each RFP or IFB rather than relying on the methapyrilene hydrochloride nominal designation.